An introduction to antiepileptic drugs

Epilepsia

Volumn 46, Issue SUPPL. 4, 2005, Pages 31-37

  Perucca, Emilio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Antiepileptic drugs; Clinical pharmacology; Drug therapy; Epilepsy; Review

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; SODIUM CHANNEL BLOCKING AGENT; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE; 4 AMINOBUTYRIC ACID; CALCIUM CHANNEL; CHLORIDE; SODIUM CHANNEL;

ANTICONVULSANT THERAPY; APLASTIC ANEMIA; ATAXIA; BLOOD DYSCRASIA; BODY WEIGHT DISORDER; COGNITIVE DEFECT; COMORBIDITY; DISEASE PREDISPOSITION; DIZZINESS; DRUG CHOICE; DRUG COST; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG SELECTIVITY; DRUG USE; EPILEPSY; FETUS MALFORMATION; GINGIVA HYPERPLASIA; HIRSUTISM; HUMAN; HYPONATREMIA; INDIVIDUALIZATION; INFANTILE SPASM; LIVER TOXICITY; MIGRAINE; NEUROPATHIC PAIN; PARESTHESIA; PREDICTION; PRIORITY JOURNAL; RASH; REVIEW; SEDATION; UROLITHIASIS; VISUAL FIELD DEFECT; WATER INTOXICATION; ADULT; BIOAVAILABILITY; DRUG EFFECT; DRUG INTERACTION; DRUG MONITORING; DRUG POTENTIATION; METABOLISM; TREATMENT OUTCOME;

ADULT; ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; CALCIUM CHANNELS; CHLORIDES; DRUG INTERACTIONS; DRUG MONITORING; DRUG SYNERGISM; EPILEPSY; GAMMA-AMINOBUTYRIC ACID; HUMANS; SODIUM CHANNELS; TREATMENT OUTCOME;

EID: 85047690079     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2005.463007.x     Document Type: Review

References (54)

1. Rochat P, Hallas J, Gaist D, et al. Antiepileptic drug utilization: a Danish prescription database analysis. Acta Neurol Scand 2001;104:6-11.
2. Schachter SC, Cramer GW, Thompson GD, et al. An evaluation of antiepileptic drug therapy in nursing facilities. J Am Geriatr Soc 1998;46:1137-41.
3. Levy RH, Mattson RH, Meldrum BS, et al. Antiepileptic drugs. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002.
4. Meldrum BS. Update on the mechanism of action of antiepileptic drugs. Epilepsia 1996;37(suppl 6):S4-11.
5. Meldrum BS. Antiepileptic drugs potentiating GABA. Electroencephalogr Clin Neurophysiol Suppl 1999;50:450-7.
6. Beghi E, Perucca E. The management of epilepsy in the 1990s: acquisitions, uncertainties, and perspectives for future research. Drugs 1995;49:680-94.
7. Perucca E. The new generation of antiepileptic drugs: advantages and disadvantages. Br J Pharmacol 1996;42:531-3.
8. Perucca E. The clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fund Clin Pharmacol 2001;15:405-7.
9. Perucca E, Gram L, Avanzini G, et al. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998;39:5-17.
10. Kuo CC, Chen RS, Lu L, et al. Carbamazepine inhibition of neuronal Na+ currents: quantitative distinction from phenytoin and possible therapeutic implications. Mol Pharmacol 1997;51:1077-83.
11. Marescaux C, Vergnese M, Bernasconi R. GABA-B receptor antagonists: potential new anti-absence drugs. J Neural Transm Suppl 1992;35:179-88.
12. Kito M, Maehara M, Watanabe K. Antiepileptic drugs: calcium current interaction in cultured human neuroblastoma cells. Seizure 1994;3:141-9.
13. Van Luijtelaar G, Wiaderna D, Elants C, et al. Opposite effects of T- and L-type Ca(2+) channels blockers in generalized absence epilepsy. Eur J Pharmacol 2000;406:381-9.
14. Fink K, Meder W, Dooley DJ, et al. Inhibition of neuronal Ca(2+) influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices. Br J Pharmacol 2000;130: 900-6.
15. Zona C, Tancredi V, Longone P, et al. Neocortical potassium currents are enhanced by the antiepileptic drug lamotrigine. Epilepsia 2002;43:685-90.
16. Madeja M, Margineanu DG, Gorji A, et al. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? Neuropharmacology 2003;45:661-71.
17. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004;101:9861-6.
18. Wellington K, Goa KL. Oxcarbazepine: an update of its efficacy in the management of epilepsy. CNS Drugs 2001;15:137-63.
19. Langtry HD, Gillis JC, Davis R. Topiramate: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 1997;94:752-73.
20. Post RM, Weiss SR. A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures. Mol Neurobil 1996;13:33-60.
21. Ketter TA, Manji HK, Post RM. Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J Clin Psychopharmacol 2003;23:484-95.
22. Guerrini R, Dravet C, Genton P, et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998;39:508-12.
23. Eadie MJ. The role of therapeutic drug monitoring in improving the cost effectiveness of anticonvulsant therapy. Clin Pharmacokinet 1995;29:29-35.
24. Perucca E, Dulac O, Shorvon S, et al. Harnessing the clinical potential of antiepileptic drug therapy: dosage optimisation. CNS Drugs 2001;15:609-21.
25. Richens A. Clinical pharmacokinetics of phenytoin. Clin Pharmacokinet 1979;4:153-69.
26. Kudriakova TB, Sirota LA, Rozova GI, et al. Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites. Br J Clin Pharmacol 1992;33:611-5.
27. Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet 2000;38:191-204.
28. Battino D, Dukes MNG, Perucca E. Anticonvulsants. In: Dukes MNG, Aronson JK, eds. Meyler's side effects of drugs, 14th ed. Amsterdam: Elsevier Science BV, 2000:164-97.
29. Leppik IE, Wolff DL. The place of felbamate in the treatment of epilepsy. CNS Drugs 1995;4:294-301.
30. Kälviäinen R, Nousiainen I. Visual field defects with vigabatrin: epidemiology and therapeutic implications. CNS Drugs 2001;15:217-30.
31. Chiron C, Dumas C, Jambaqué I, et al. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 1997;26:389-95.
32. Perucca E, Beghi E, Dulac O, et al. Assessing risk to benefit ratio in antiepileptic drug therapy. Epilepsy Res 2000;41:107-39.
33. Besag FMC. Approaches to reducing the incidence of lamotrigine-induced rash. CNS Drugs 2000;13:21-3.
34. Zahn CA, Morrell MJ, Collins SD, et al. Management issues for women with epilepsy: a review of the literature. Neurology 1998;51:949-56.
35. Holmes L, Wyszynski D, Mittendorf R. Evidence for an increased risk of birth defects in the offspring of women exposed to valproate during pregnancy: findings from the AED pregnancy registry [Abstract]. Abstr Am J Obstet Gynecol 2002;187(suppl):S137.
36. Morrow JI, Craig JJ, Russell AJC, et al. Which antiepileptic drugs are safest in pregnancy? Abstr Epilepsia 2003;44(suppl 8):60.
37. Tomson T, Perucca E, Battino D. Navigating toward fetal and maternal health. The challenge of treating epilepsy in pregnancy. Epilepsia 2004;45:1171-5.
38. Perucca E. Overtreatment in epilepsy: adverse consequences and mechanisms. Epilepsy Res 2002;52:25-33.
39. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003;2:347-56.
40. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003;2:473-81.
41. Spina E, Perucca E. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia 2002;43(suppl 2):37-4.
42. Shorvon SD, Tallis RC, Wallace HK. Antiepileptic drugs: coprescription of proconvulsant drugs and oral contraceptives: a national study of antiepileptic drug prescribing practice. J Neurol Neurosurg Psychiatry 2002;72:114-5.
43. Vecht CJ, Wagner L, Wilms EB. Interactions between antiepileptic and chemotherapeutic agents. Lancet Neurol 2003;2:404-9.
44. Pisani F, Fazio A, Oteri G, et al. Sodium valproate and valpromide: differential interactions with carbamazepine in epileptic patients. Epilepsia 1986;27:548-52.
45. Perucca E. Established antiepileptic drugs. In: Brodie MJ, Treiman DM, eds. Modern management of epilepsy, Baillière's clinical neurology, Vol 5. London: Baillière-Tindall, 1996:693-722.
46. Besag FMC, Berry DJ, Pool F, et al. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia 1998;39:183-7.
47. Brodie MJ, Yuen AWC, 105 Study Group. Lamotrigine substitution study: evidence for synergism with sodium valproate. Epilepsy Res 1997;26:423-32.
48. Pisani F, Oteri G, Russo MF, et al. The efficacy of valproatelamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 1999;40:1141-6.
49. Brodie MJ, Overstall PW, Giorgi L, and the UK Lamotrigine Elderly Study Group. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsy Res 1999;37:81-7.
50. Perucca E. Current trends in antiepileptic drug therapy. Epilepsia 2003;44(suppl 4):41-7.
51. Perucca E. NICE guidance on newer drugs for epilepsy in adults. Br Med J 2004;328:1273-4.
52. Evins AE. Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. J Clin Psychiatry 2003;64(suppl 8): 9-14.
53. Pappagallo M. Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine. Clin Ther 2003;25:2506-38.
54. Perucca E. Established antiepileptic drugs. In: Brodie MJ, Treiman DM, eds. Modern management of epilepsy. Baillière's clinical neurology. Vol 5. London: Baillière-Tindall, 1996:693-722.